Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial

Andrea Kuhnl, MD, Clare Peckitt, Bijal Patel, Kirit M Ardeshna, MD, Marian P Macheta, John Radford, MD, Rod Johnson, Shankaranarayana Paneesha, Sarah Barton, Ian Chau, MD, Martin F Kaiser, MD, Ruwaida Begum, Nicola Valeri, Andrew Wotherspoon, Yong Du, Imene Zerizer, David Cunningham, MD FRCP

Blood (2017) 130 (Supplement 1): 2829.

https://doi.org/10.1182/blood.V130.Suppl_1.2829.2829

Published: 2017

Journal Articles

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Carmelo Carlo-Stella, MD, Erin Reid, MD, Jay Feingold, MD PhD, Kirit M Ardeshna, MD, John Radford, MD, Melhem M Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, Shui He, PhD, Joseph Boni, PhD, Owen Anthony O'Connor, MD

Blood (2017) 130 (Supplement 1): 187.

https://doi.org/10.1182/blood.V130.Suppl_1.187.187

Published: 2017

Journal Articles

Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience

Raakhee Shah, MPharm, Simon Cheesman, BPharm, Kirit M Ardeshna, MD, Kate Cwynarski, MD, David C. Linch, FRCP, Andres E. Virchis, FRCP, FRCPath, Jonathan Richard Lambert, Christopher Mcnamara, William Townsend

Blood (2017) 130 (Supplement 1): 3387.

https://doi.org/10.1182/blood.V130.Suppl_1.3387.3387

Published: 2017

Journal Articles

Clinical Outcomes of Phase I/II Clinical Trials for Patients with Relapsed/Refractory Haematological Malignancies: Experience of an Early Phase Clinical Trials Unit

Chin-Hin Ng, MD MRCP, FRCPATH, Dima El-Sharkawi, MD, Elspeth M Payne, MDPhD, Kwee L Yong, Kirit M Ardeshna, MD FRCP, FRCPATH, Asim Khwaja, FRCPath, Rakesh Popat

Blood (2016) 128 (22): 3613.

https://doi.org/10.1182/blood.V128.22.3613.3613

Published: 2016

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Excess Late Gastrointestinal Toxicity Associated with Leam Conditioning Compared to BEAM for Autologous Stem Cell Transplantation in Lymphoma, a Single Institution Experience

Jaimal Kothari, FRCPath, Michael Foley, MBBS, Karl S Peggs, Kirsty Thomson, Emma Morris, FRCPath, Kirit M Ardeshna, MD FRCPath, Andres E. Virchis, FRCPath, David C Linch, FMedSci, Jonathan Lambert, FRCPath

Blood (2014) 124 (21): 5898.

https://doi.org/10.1182/blood.V124.21.5898.5898

Published: 2014

Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci

Blood (2014) 124 (21): 1723.

https://doi.org/10.1182/blood.V124.21.1723.1723

Published: 2014

Journal Articles

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Ian Flinn, Nancy L. Bartlett, MD, Kristie A. Blum, MD, Kirit M Ardeshna, MD FRCPath, Ann LaCasce, MD, Christopher R. Flowers, MD, Andrei R. Shustov, MD, Kenneth Thress, PhD, Fred Zheng, MD PhD, Jeffery Skolnik, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 1725.

https://doi.org/10.1182/blood.V124.21.1725.1725

Published: 2014

Journal Articles

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Poornima Kumar, MBBS, Rebekah Ahmed, MBBS, Renu Riat, MBBS, Kirit M Ardeshna, MD, Stephen Daw, MBChb

Blood (2012) 120 (21): 4784.

https://doi.org/10.1182/blood.V120.21.4784.4784

Published: 2012

Journal Articles

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Kirit M Ardeshna, MD, Peter Hoskin, Paul Smith, PhD, Nicholas Chadwick, Nivette Braganca, Wai-Lup Wong, MD, Irfan Kayani, Bal Sanghera, Patricia Diez, Helen Lucraft, Andrew Jack, PhD, MB, Christopher J McNamara, George Mikhaeel, MD, Scott Marshall, MD, Ruth Pettengell, Robert E. Marcus, MBBS, FRCP, FRCPath, Anton Kruger, David C Linch, MD FMedSci

Blood (2012) 120 (21): 1621.

https://doi.org/10.1182/blood.V120.21.1621.1621

Published: 2012

Journal Articles

Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

Jaimal Kothari, MD, Antonia Ljubic, BSc, Karl S Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Andres E. Virchis, MD, Jonathan Lambert, MD, Anthony H Goldstone, MD, David C Linch, MD FMedSci, Kirit M Ardeshna, MD

Blood (2011) 118 (21): 2025.

https://doi.org/10.1182/blood.V118.21.2025.2025

Published: 2011

Journal Articles

Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma

Kirsty Thomson, Irfan Kayani, Kirit M Ardeshna, MD, Emma Morris, MD, Rachael Hough, Anthony H Goldstone, MD, David C Linch, MD FMedSci, Karl S Peggs, MD

Blood (2011) 118 (21): 336.

https://doi.org/10.1182/blood.V118.21.336.336

Published: 2011

Journal Articles

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

Karl S Peggs, Irfan Kayani, Kirsty Thomson, Emma Morris, MD, Panagiotis Kottaridis, Kirit M Ardeshna, MD, Adele Fielding, Rachael Hough, Anthony H Goldstone, MD, Ronjon Chakraverty, David C Linch, MD FMedSci, Stephen Mackinnon

Blood (2011) 118 (21): 2016.

https://doi.org/10.1182/blood.V118.21.2016.2016

Published: 2011

Journal Articles

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Kirit M Ardeshna, MD, Wendi Qian, Paul Smith, June Warden, Lindsay Stevens, Christopher FE Pocock, MD, PhD, Fiona Miall, MD, David Cunningham, MD, John Davies, MD, Jan Walewski, A. Burhan Ferhanoglu, MD, Ken Bradstock, MB, PhD, David C Linch, MD, FMedSci

Blood (2010) 116 (21): 6.

https://doi.org/10.1182/blood.V116.21.6.6

Published: 2010

Journal Articles

Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)

Andrew Hodson, MD, Silvia Montoto, MD, Naheed Mir, MD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Kate Cwynarski, MD, PhD, Kirit M Ardeshna, MD, Thurai Kumaran, MD, Estella Matutes, MD, PhD, Graham Talyor, MD, Paul Fields, MD, PhD

Blood (2010) 116 (21): 3961.

https://doi.org/10.1182/blood.V116.21.3961.3961

Published: 2010

NARROW

R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience

Clinical Outcomes of Phase I/II Clinical Trials for Patients with Relapsed/Refractory Haematological Malignancies: Experience of an Early Phase Clinical Trials Unit

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Excess Late Gastrointestinal Toxicity Associated with Leam Conditioning Compared to BEAM for Autologous Stem Cell Transplantation in Lymphoma, a Single Institution Experience

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only